Dr. Ward is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-3250
Summary
- Dr. Ward is a clinical scientist with exclusive focus on the management of prostate and testicular cancers. He is recognized as one of the early thought leaders in the prostate cancer imaging and focal therapy. His contributions laid the ground work that has helped this approach gain recognition as an acceptable therapeutic strategy for select patients with prostate cancer. He helped develop ablative techniques using variety of energy and imaging techniques including the early studies of interstitial laser ablation, focal cryotherapy and high-intensity focused ultrasound; the later work leading to the FDA US approval. He is equally involved in development of urine and blood bio-markers of prostate cancer and now image guided targeted prostate biopsy. As a busy clinician, Dr. Ward not only pioneered the MD Anderson Cancer Center Prostate cancer imaging and focal therapy program while performing 200+ robotic assisted prostatectomies a year, but he also developed the MD Anderson technique of robotic retroperitoneal lymph node dissection and has now expanded this surgery into both the post-chemotherapy setting and as primary treatment for metastatic seminoma.
A native of Pittsburgh, Pennsylvania, Dr. Ward is a Graduate of the University of Notre Dame and Georgetown Medical School. He received his urologic oncology training at the Mayo Clinic, Rochester, Minnesota before completing a career with the US Navy. He joined the faculty at M.D. Anderson Cancer Center in 2006.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Minimally Invasive Urologic Surgery, 2001 - 2003
- Naval Medical Center (San Diego)Residency, Urology, 1993 - 1998
- Naval Medical Center (San Diego)Internship, Transitional Year, 1991 - 1992
- Georgetown University School of MedicineClass of 1991
Certifications & Licensure
- CA State Medical License 1992 - Present
- FL State Medical License 2021 - Present
- TX State Medical License 2006 - 2026
- AZ State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- OK State Medical License 2020 - 2025
- WA State Medical License 2023 - 2025
- American Board of Urology Urology
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Prostate Conformal Cryotherapy Start of enrollment: 2009 Apr 06
- A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer Start of enrollment: 2011 Jan 27
- Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Start of enrollment: 2011 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 424 citationsVISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Zhichang Shi, Sumit K. Subudhi
Nature Medicine. 2017-03-27 - 144 citationsSALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: CONTEMPORARY OUTCOMESJohn F. Ward, Thomas J. Sebo, Michael L. Blute, Horst Zincke
The Journal of Urology. 2005-04-01 - 193 citationsConstraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks.David J. Brenner, John F. Ward
International Journal of Radiation Biology. 1992-06-01
Other
- Initial management of regionally localized intermediate and high risk prostate cancerWard JF, Davis B, Vogelzang N
http://www.uptodate.com/contents/initial-management-of-regionally-localized-intermediate-and-high-ri
UpToDate, Wolters Kluwer Health - 2013-02-25 - Pathologic stage T3 and margin positive prostate cancerWard JF, Davis B, Vogelzang N
http://www.uptodate.com/contents/pathologic-stage-t3-and-margin-positive-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-01-03
Press Mentions
- Focal Therapy for Prostate Ca: Ready for Prime Time?October 5th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: